Vaccine development is our best bet to tackle epidemic outbreaks and pandemics.
Despite recent mobilization, vaccine development is still time consuming and complex. Researchers still have limited access to capabilities to transfer their discovery into clinical development and commercialization.
TRANSVAC Network is equipped to support the acceleration of successful vaccine businesses
Track record of value chain and transversal services
- Assays & Models
- Technology
- Adjuvants
- Regulatory and Clinical expertise
- Training
- Network
TRANSVAC’s path forward is to focus on business building
- Active investor scouting and outreach support
- Evaluating commercial viability
- Portfolio Management
- Funding
- Business Building and Coaching
TRANSVAC delivers commercial impact at scale as a vaccine business building entity
Connect
URL: www.transvac.org/
e-mail: transvacinfo@euvaccine.eu
Telf: +49 17660863372
Sign up for the EVI newsletter at https://www.transvac.org/news
Learn more about TRANSVAC-2 and TRANSVAC-DS Research Projects
Network: 25 Partners; Funder: European Union; Timeline: 1 June 2020 – 31 May 2022; Coordinator: European Vaccine Initiative This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N° 951668.